The report highlights Takeda's commitment to its corporate purpose of better health for people and a brighter future for the world. The company achieved significant milestones in 2022, including the approval of its dengue vaccine QDENGA® in the European Union. The report also highlights Takeda's progress towards its net-zero emissions goals, its commitment to responsible innovation, and its efforts to ensure equitable access to its products and services.
Issuing Company Takeda Pharmaceutical Co., Ltd.
Report Type Integrated Report
Report Language EN
Report Filesize 5.44 MB
No. of Pages 60 pages
Reporting periodFiscal Year ended March 31, 2023
Report EditionUnknown
Assurance Provider KPMG AZSA Sustainability Co., Ltd. (KPMG)
Reporting Standards GRI; SASB; UNGC; others
Materiality Assessmenttrue